Drug intelligence / Profile preview

BrainPhyt

Development stage: Unknown
Lead developer: Microphyt
Administration: Oral

Overview

BrainPhyt is a standardized microalgae extract derived from the diatom *Phaeodactylum tricornutum*, specifically developed to support cognitive health and mitigate age-related cognitive decline. The extract is standardized to contain 2% fucoxanthin, a marine carotenoid, along with polyunsaturated omega-3 fatty acids. Its mechanism of action involves neuroprotection through the regulation of oxidative stress and the inhibition of pro-inflammatory cytokines such as TNF-α and IL-6. Clinical studies have evaluated its efficacy in improving spatial working memory, attention, and mood in healthy older adults.

Brand names: BrainPhyt
Other names: Phaeodactylum tricornutum extractPT extract

Targets

TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)

Beyond the preview

Go deeper on BrainPhyt.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BrainPhyt.

Explore the full profile